Dr Deborah O’Neil is the CEO of Novabiotics, a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives.

She recently delivered a talk on the pharmaceutical industry as it is today, and offered an insight into what it could become, with a focus on so-called ‘personalised medicines’.

She also addressed the worrying issue of antimicrobial resistance and discussed new cancer therapies being approved by the NHS.

This is Five Minutes with Dr Deborah O'Neil.